HPV vaccine development after more than ten years approval

Abstract

<jats:p>At present, ten years have passed since the human papillomavirus (HPV) vaccine was first approved for use in humans. Research related to HPV vaccine, both in terms of effectiveness and immugenicity in its development, has been widely carried out, such as in terms of the indications of the HPV vaccine use that is not only for preventing cervical cancer, the guidelines for administering 2-dose HPV vaccines for those under 15 years of age, and the discovery of the latest HPV vaccine types: nonavalent HPV vaccine. This review literature discusses all aspects of the development of HPV vaccine since it was first approved for use in humans in 2006.</jats:p>

Attitude and Family Support Influenced Human Papilloma Virus Vaccination in Female Midwifery Students

“…There are currently 3 types of HPV vaccines, namely bivalent, tetravalent, and nanovalent which are able to provide protection from 9 types of HPV virus (Askandar, 2020). Bivalent and tetravalent vaccines have received marketing authorization since 2006, and are used in more than 200 countries.…”